Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.35 |
| ▸ | HTR2A | P28223 | 6/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.34 |
| ▸ | HTR2C | P28335 | 6/20 | 0.32 |
| ▸ | HTR6 | P50406 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6644958 | 1.00 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3HTR2AKCNH2 | |
| SCHEMBL6648739 | 0.91 | HTR2A (0.35) | SLC6A2SLC6A4SLC6A3HTR2AKCNH2 | |
| SCHEMBL6670554 | 0.91 | HTR2A (0.35) | SLC6A2SLC6A4SLC6A3HTR2AKCNH2 | |
| SCHEMBL6671004 | 0.85 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3HTR2AKCNH2 | |
| SCHEMBL6673048 | 0.85 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3HTR2AKCNH2 | |
| SCHEMBL6669880 | 0.85 | HTR6 (0.33) | HTR2CHTR6 | |
| SCHEMBL6669048 | 0.85 | HTR6 (0.33) | HTR2CHTR6 | |
| SCHEMBL6669869 | 0.84 | HTR2A (0.35) | SLC6A2SLC6A4SLC6A3HTR2AKCNH2 | |
| SCHEMBL6674279 | 0.84 | HTR2A (0.35) | SLC6A2SLC6A4SLC6A3HTR2AKCNH2 | |
| SCHEMBL6670302 | 0.83 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762191-B2 | TREATING DISEASES FOR MODULATING OF 5-HT ACTIVITY, CENTRAL NERVOUS SYSTEM DISORDERS, ANXIETY, OBESITY, DEPRESSION, OR A STRESS-RELATED DISEASE | PHARMACIA & UPJOHN COMPANY | 2004-07-13 | — | — | US | claimed |
| US-20030050304-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2003-03-13 | — | — | US | claimed |
| US-20040214815-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | disclosed |
| US-6762191-B2 | TREATING DISEASES FOR MODULATING OF 5-HT ACTIVITY, CENTRAL NERVOUS SYSTEM DISORDERS, ANXIETY, OBESITY, DEPRESSION, OR A STRESS-RELATED DISEASE | PHARMACIA & UPJOHN COMPANY | 2004-07-13 | — | — | US | disclosed |
| US-20030050304-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214815-A1 | Therapeutic compounds | HTR5A, HTR6, HTR1A | SLC6A2 128/4885SLC6A4 47/4885SLC6A3 169/4885 |
| US-20030050304-A1 | Therapeutic compounds | HTR5A, HTR6, HTR1A | SLC6A2 128/4885SLC6A4 47/4885SLC6A3 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.